Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search